Retatrutide vs Orforglipron (Foundayo): Triple Agonist vs Oral GLP-1

Overview

Retatrutide and orforglipron (brand name Foundayo) are both Eli Lilly obesity drugs, but they take very different approaches. Retatrutide (LY3437943) is an investigational injectable triple agonist that targets the GIP, GLP-1 and glucagon receptors, built to get the most weight loss possible from acting on several receptors. Orforglipron (Foundayo) is an FDA-approved oral GLP-1 receptor agonist. It is a small molecule rather than a peptide, and it was approved on April 1, 2026, for obesity and overweight in adults.

Both now have Phase 3 data, so the efficacy gap is firmly established. Retatrutide reported Phase 3 results from TRIUMPH-1 (-28.3% at 80 weeks, May 21, 2026) and TRIUMPH-4 (-28.7% at 68 weeks, December 2025). Orforglipron’s Phase 3 ATTAIN-1 showed -12.4% weight loss (efficacy estimand) at 17.2 mg. Retatrutide produces about 2.3× the average weight loss of Foundayo. The two do not compete inside Eli Lilly’s lineup. They serve different patients: Foundayo (FDA-approved and on the market since April 2026) for access and convenience, retatrutide for maximum efficacy once it arrives in 2027-2028.

Important note: No clinical trial has compared retatrutide with orforglipron directly. All comparisons here are cross-trial, with major methodological limits.

Why This Comparison Matters

This comparison matters for more than the obvious efficacy gap:

• Orforglipron (Foundayo) is FDA-approved and on the market, while retatrutide is still in Phase 3 development. This is the first time the comparison pits an approved drug against an investigational one
• Together with tirzepatide (Mounjaro/Zepbound), they form a three-tier treatment model that matches treatment intensity to disease severity and patient preference
• It raises a basic question in obesity medicine: is it better to treat more people with a moderately effective pill, or fewer people more aggressively with a highly effective injection?
• Foundayo’s pricing (as of October 2026: $25/month with commercial coverage and a savings card; self-pay $149 to $349/month depending on dose) sets a new bar for access that retatrutide will have to answer when approved

Mechanism of Action

Orforglipron (Foundayo)

Orforglipron is a breakthrough because it is not a peptide. Every earlier approved GLP-1 receptor agonist (semaglutide, liraglutide, tirzepatide) is a modified peptide that has to be injected or given in a special oral formulation. Orforglipron is a small-molecule, non-peptide agonist of the GLP-1 receptor.

Key features:

• Selective GLP-1 receptor activation, which suppresses appetite, boosts glucose-dependent insulin secretion, lowers glucagon and slows gastric emptying
• Absorbed when swallowed without the absorption-enhancing technology in oral semaglutide (Rybelsus), which depends on the SNAC excipient and strict fasting rules
• Once-daily oral dosing, giving steady GLP-1 receptor activation through the day
• No GIP or glucagon receptor activity; it targets a single receptor

Orforglipron’s innovation lies in how it is delivered, not in which receptors it hits. It activates the GLP-1 receptor through a new molecular scaffold that survives the gut and reaches effective blood levels when taken by mouth.

Retatrutide

Retatrutide targets three receptors at once with a single injectable peptide:

• GLP-1 receptor activation provides the appetite and blood sugar effects it shares with orforglipron
• GIP receptor activation adds fat tissue remodeling, more insulin secretion and further appetite control in the brain
• Glucagon receptor activation raises energy use through heat production and fat burning in the liver

The contrast is sharp: orforglipron acts on one receptor via a convenient pill, while retatrutide acts on three via a weekly injection. That sets up a clear trade-off between efficacy and convenience, which defines the role of each.

Efficacy Comparison

Weight Loss

TRE = treatment-regimen estimand (intent-to-treat, includes all randomized participants regardless of adherence). ATTAIN-1 tested a 36 mg capsule; Lilly says this matches the approved 17.2 mg tablet, which absorbs better.

The efficacy gap is large and expected from how the drugs work. At Phase 3 doses, retatrutide’s three-receptor action produces more than double the average weight loss of orforglipron’s single receptor. Acting on several receptors, and especially adding glucagon-driven energy use, has bigger metabolic effects than GLP-1 receptor activation alone, however the drug is delivered.

Still, orforglipron’s roughly 11-12% weight loss (-11.2% treatment-regimen estimand, -12.4% efficacy estimand) is clinically significant and beats most earlier approved obesity drugs. For many people, that is enough for real health gains, including lower cardiovascular risk, less sleep apnea and better blood sugar control.

Glycemic Control

Both drugs improve blood sugar in people with type 2 diabetes:

• Orforglipron lowered HbA1c by about 1.6% in Phase 2 diabetes studies
• Retatrutide lowered HbA1c by 1.86 and 1.94 percentage points at the 9 mg and 12 mg doses in TRANSCEND-T2D-1 (Phase 3, 40 weeks)

The gap in blood sugar control is smaller than the gap in weight loss, because GLP-1 receptor activation on its own is a strong driver of glucose control.

Liver Fat

Retatrutide’s glucagon component gives it a big advantage on liver fat (~82% relative reduction in Phase 2). Orforglipron, a selective GLP-1 agonist, should lower liver fat mainly through weight loss, similar to the moderate reductions seen with semaglutide. For people with both obesity and MASLD/MASH, that difference may matter.

Safety Comparison

Gastrointestinal Tolerability

In ATTAIN-1, published in NEJM, the most common side effects of orforglipron were gastrointestinal and mostly mild to moderate. In TRIUMPH-4, the 12 mg retatrutide group reported nausea in 43.2%, diarrhea in 33.1%, vomiting in 20.9% and constipation in 25.0%. We have not been able to confirm ATTAIN-1’s per-event rates from the paper, so we do not compare them here. Daily orforglipron and weekly retatrutide produce different blood-level patterns, which may affect how GI effects show up.

TRIUMPH-4 Safety Signal: Dysesthesia

TRIUMPH-4 found a new safety signal for retatrutide: dysesthesia (abnormal sensations such as numbness, tingling or burning) in 20.9% of participants at 12 mg versus 0.7% on placebo. It needs further study in ongoing trials. Orforglipron has not shown a similar signal in its development.

Route-Specific Considerations

Orforglipron (Foundayo) advantages:

• No injection-site reactions (erythema, nodules, pruritus)
• No injection training, needle disposal or cold-chain storage
• Fear of needles is no longer a barrier
• Simpler supply chain and distribution

Retatrutide advantages:

• Once-weekly dosing may help adherence compared with a daily pill
• No fasting or special timing around meals (unlike oral semaglutide)
• Injection gives reliable absorption, unaffected by GI conditions, food or variable uptake

Pricing and Access

Price and availability are now among the biggest differences between the two:

Foundayo costs far less than the injectables’ list prices: Wegovy’s was $1,349 a month as of February 2026, and Zepbound’s has been above $1,000 a month since its 2023 launch. Self-pay prices for the injectables are lower; on LillyDirect, Zepbound runs $299 to $449 a month by dose as of October 2026. This pricing puts oral GLP-1 treatment within reach of many more people.

Retatrutide’s price has not been announced. As an injectable peptide that is harder to manufacture and more effective, it will probably cost more than Foundayo, but it will have to compete in a market under growing price pressure.

Administration and Convenience

Foundayo’s convenience is a real advantage, and it has already widened the pool of people willing to start an obesity drug. Many who turn down injections will take a pill, which helps close the big gap between the number of people who qualify for treatment and the number who get it.

Eli Lilly Portfolio Strategy

Retatrutide and orforglipron fill complementary roles in Eli Lilly’s lineup:

• Orforglipron (Foundayo) aims at the widest possible patient group by removing the injection barrier. Now approved and on the market, it is the accessible first-line option that brings the most people into drug treatment.
• Retatrutide aims at people who need the most efficacy possible: those with severe obesity, significant metabolic conditions or MASLD, where three-receptor action gives the most benefit.
• Tirzepatide (Mounjaro/Zepbound) sits between them as the established, approved dual agonist.

This three-tier approach lets Eli Lilly serve different parts of the obesity market: people who want convenience (Foundayo), proven efficacy (tirzepatide) and maximum efficacy (retatrutide).

Current Status and Availability

Orforglipron (Foundayo)

Orforglipron won FDA approval on April 1, 2026, under the brand name Foundayo, for obesity and overweight in adults. It is the first oral non-peptide GLP-1 receptor agonist on the market. Phase 3 ATTAIN-1 showed -12.4% weight loss at the 17.2 mg dose (efficacy estimand; -11.2% treatment-regimen estimand). As of October 2026, Foundayo costs as little as $25 per month for commercially insured patients with a savings card, and $149 to $349 per month self-pay through LillyDirect, depending on dose.

Retatrutide

Retatrutide is still in Phase 3 development through the TRIUMPH program (obesity), the TRANSCEND program (type 2 diabetes) and the SYNERGY/MACELD program (liver disease). TRIUMPH-4 topline results were announced in December 2025. TRANSCEND-T2D-1 topline results were announced on March 19, 2026, and published in The Lancet on June 6, 2026. TRIUMPH-1, the pivotal obesity trial in 2,339 adults without diabetes, reported on May 21, 2026: -28.3% mean weight loss at 12 mg over 80 weeks, with all three doses meeting primary endpoints. TRIUMPH-2 (obesity + T2D, -20.8% at 12 mg) and TRIUMPH-3 (severe obesity + CVD, -22.6%) reported on July 23, 2026, completing the pivotal program. Eli Lilly plans to file for approval no later than Q1 2027, with possible approval in late 2027 to early 2028. The FDA ruled on October 2, 2026 that retatrutide is a drug, so the application must be a New Drug Application (NDA), which Lilly is contesting (the FDA ruling). Available only through clinical trials.

Key Differences Summary

The Efficacy-Convenience Trade-Off in Practice

Choosing between retatrutide and Foundayo comes down to one of medicine’s oldest tensions: maximum efficacy versus maximum convenience. With Foundayo approved and on sale, that trade-off is now practical rather than theoretical.

Real-World Implications

With Foundayo on the market, patients and clinicians can already decide along these lines:

• People with mild-to-moderate obesity, a dislike of needles or a preference for pills can start Foundayo today at an affordable price
• People with severe obesity, significant metabolic conditions or MASLD who need maximum weight loss will have to wait for retatrutide’s approval or join a clinical trial
• Some may start on Foundayo and move to retatrutide when it arrives, if they need more efficacy
• Price will shape many choices: Foundayo’s self-pay price starts at $149/month, while injectable list prices are above $1,000/month (self-pay Zepbound on LillyDirect: $299 to $449/month as of October 2026)

Patient Preference Data

Surveys consistently show that:

• 20-30% of patients eligible for injectable GLP-1 therapy decline due to needle aversion
• Daily oral medications have typical adherence rates of 50-70% over one year
• Weekly injectable medications have adherence rates of 60-80% over one year
• Patient satisfaction and treatment persistence are strongly correlated with perceived efficacy

So both pills and injections have important roles, and the best choice depends on the individual.

What These Two Drugs Mean for Obesity Treatment

With Foundayo approved and retatrutide expected in 2027-2028, Eli Lilly’s three-tier treatment model is taking shape:

1. First-line oral therapy: Foundayo (orforglipron) for people with mild-moderate obesity or who prefer a pill. Available now
2. Established injectable therapy: Tirzepatide (Zepbound) for people who need more weight loss than a pill provides. Available now
3. Maximum-efficacy injectable therapy: Retatrutide for people with severe obesity, significant metabolic conditions or MASLD. Expected late 2027 to mid-2028

This mirrors how other chronic diseases are managed, with treatment intensity matched to disease severity.

Frequently Asked Questions

Is orforglipron (Foundayo) FDA-approved?

Yes. Orforglipron won FDA approval on April 1, 2026, under the brand name Foundayo, for obesity and overweight in adults. It is the first oral non-peptide GLP-1 receptor agonist on the market. Phase 3 ATTAIN-1 showed -12.4% weight loss at 17.2 mg (efficacy estimand; -11.2% treatment-regimen estimand). It is available through LillyDirect.

How much does Foundayo cost compared to injectable treatments?

As of October 2026, Foundayo costs as little as $25 per month for commercially insured patients with a savings card, and self-pay prices through LillyDirect run from $149 per month for the lowest dose to $349 for the highest. Since July 1, 2026, Medicare Part D enrollees who meet CMS criteria can get it for $50 a month through the Medicare GLP-1 Bridge. That is far below the list prices of injectables such as Wegovy ($1,349 a month as of February 2026) and Zepbound (above $1,000 a month). Retatrutide has no announced price because it is still investigational.

How much more weight loss does retatrutide produce compared to Foundayo?

Much more: -28.7% in Phase 3 (TRIUMPH-4, 68 weeks at 12 mg) versus Foundayo’s -12.4% (ATTAIN-1, efficacy estimand at 17.2 mg). The difference comes from retatrutide’s three-receptor action, which both reduces appetite and raises energy use through the glucagon receptor.

Can I take Foundayo now and switch to retatrutide later?

It is a reasonable idea. Foundayo is available now, so you could start the pill while waiting for retatrutide’s approval. But switching between these drugs has not been studied in clinical trials. Any change would need medical supervision, and no washout or switching protocol has been set.

Why would someone choose Foundayo over waiting for retatrutide?

Several practical reasons favor starting Foundayo now. It is FDA-approved and available immediately. Self-pay starts at $149/month for the lowest dose as of October 2026 (or as little as $25/month with commercial coverage). It needs no injections. And 12% weight loss is clinically meaningful for many people. Retatrutide is not expected to be approved until late 2027 at the earliest, and it will likely cost much more. If you need or want to start treatment now, Foundayo is an accessible option.

Are both drugs made by Eli Lilly?

Yes. Eli Lilly and Company develops and manufactures both orforglipron (Foundayo) and retatrutide. They are designed to complement each other in different parts of the obesity market: Foundayo for access and convenience, retatrutide for maximum efficacy.